MICHELLE ADLER: Open Payments
NPI 1730510652 · ALBUQUERQUE, NM. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 27 payments from 8 companies in 2025. Trend: 2023 $237 · 2024 $342 · 2025 $946
Food & beverage: $946
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $431 |
| AstraZeneca Pharmaceuticals LP | 3 | $147 |
| ABBVIE INC. | 11 | $137 |
| Otsuka America Pharmaceutical, Inc. | 1 | $92 |
| Novo Nordisk Inc | 1 | $73 |
| Lilly USA, LLC | 1 | $31 |
| Abbott Laboratories | 1 | $21 |
| E.R. Squibb & Sons, L.L.C. | 1 | $15 |
Products named: CAPLYTA, VRAYLAR, AIRSUPRA, REXULTI, Wegovy, ZEPBOUND, FREESTYLE LIBRE 3, COBENFY.
Industry payments across NM — which companies pay providers there.
